A. Tutt
7 Papers
3 Citations
A. Tutt is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
Charles E. Geyer,Judy Garber,R. D. Gelber,Greg Yothers,M Taboada,Louetta A. Ross,PS Rastogi,Karen Y. Cui,Amal Arahmani,Gursel Aktan,A. Armstrong,Monica Arnedos,Judith Balmaña,Joop P. W. van den Bergh,J. Bliss,S. Delaloge,S. Domchek,Andrea Eisen,F. Elsafy,Luis Fein,Anitra Fielding,James M. Ford,S. Friedman,Karen A. Gelmon,L. Gianni,Michael Gnant,Simon J. Hollingsworth,Sa Im,Agnes Jager,Oskar T. Johannsson,Sunil R. Lakhani,Wolfgang Janni,Barbro Linderholm,T-W. Liu,Niklas Loman,Larissa A. Korde,S. Loibl,P. Lucas,Frederik Marmé,Eduardo Martínez de Dueñas,Robin McConnell,Kelly-Anne Phillips,Martine Piccart,Giovanna Rossi,R. K. Schmutzler,Elżbieta Senkus,Z Shao,Paramananda Dash Sharma,C. Singer,Tanja Spanic,Elmar Stickeler,Masakazu Toi,TA Traina,Giuseppe Viale,Gabriele Zoppoli,Y. Park,Rinat Yerushalmi,H Yang,Dan-mei Pang,KH Jung,A. Mailliez,Zusen Fan,Isabelle Tennevet,G. Q. Zhang,Tauana Nagy,GS Sonke,Q. Sun,Marina Parton,Marco Colleoni,M. Schmidt,Adam Brufsky,Wajeeha Razaq,Bela Kaufman,D. Cameron,Carolyn Campbell,A. Tutt +75 more
TL;DR: The randomized OlympiA trial as discussed by the authors compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in BRCA1/2pv and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer.
261
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.
S. Loibl,F. André,T. Bachelot,Carlos Barrios,J. Bergh,HJ Burstein,L.M.J. Cardoso,L. Carey,S. Dawood,L. Del Mastro,C. Denkert,E.M. Fallenberg,P.A. Francis,H. Gamal-Eldin,Karen E. Gelmon,C. E. Geyer,M. Gnant,V. Guarneri,S. Gupta,S.B. Kim,D. Krug,M. Martin,I. Meattini,M. Morrow,W. Janni,Shani Paluch-Shimon,A. Partridge,Philip Poortmans,L. Pusztai,M.M. Regan,Joseph A. Sparano,Tanja Spanic,S. Swain,S. Tjulandin,M. Toi,D. Trapani,A. Tutt,B. H. Xu,Giuseppe Curigliano,N. Harbeck +39 more
TL;DR: This ESMO Clinical Practice Guideline provides recommendations for diagnosing, treating, and following up with early breast cancer patients, aiming to improve cure rates and outcomes, particularly in younger age groups and specific subtypes.
209
Molecular biology (pre-clinical)
Luca Malorni,Mario Giuliano,I. Migliaccio,Chad J. Creighton,Mathieu Lupien,SG Hilsenbeck,X. Fu,M. Trivedi,CK Osborne,Rachel Schiff,S. Toffoli,I. Bar,F. Abdulsater,P. Delrée,P. Hilbert,Jose A. Carrasco,J. Canon,A. Grigoriadis,P. Gazinska,M. Rasmussen,A. Isaksson,E. de Rinaldis,S. Mathew,P. Marra,C. Gillett,S. Pinder,A. Tutt,P.H. Cottu,F. Assayag,O. Chouchane-Mlik,F. Reyal,P. de Cremoux,D. Gentien,S. Chateau-Joubert,A. Vincent-Salomon,D. Decaudin,Elisabetta Marangoni,E. Tokuda,Y. Seino,M. Saito,F. Kasumi,S. Hayashi,Y. Yamaguchi,A.M. Supernat,A. Markiewicz,A. Sejda,B. Seroczynska,J. Skokowski,J. Szade,M. Welnicka-Jaskiewicz,P. Nastaly,N. Bednarz-Knoll,A.J. Zaczek,A. Chakraborty,A. Mukhopadhyay,D. Bhattacharyya,K. Choudhuri,S. Mukhopadhyay,S. Gangopadhyay,J. Basak,M. Ksiązkiewicz,K. Feldinger,J. Kerry,M. Gijsen,G. Murphy,A. Kong,Y. Du,J. Lu,A. Larsson,S. Schiebel,M. Vaapil,J. Sun,A. Jögi,L. Rönnstrand,S. Påhlman,D. Allard,M. Lacroix-Triki,G. Maillot,L. Mhamdi,S. Pierredon,F. Obrist,A. Goubar,H. Roche,F. André,S. Vagner,E. Rovida,V. Barbetti,A. Morandi,M. Riverso,S. Bessi,A. Giannini,A. Di Leo,P. Dello Sbarba,C. Thuwajit,K. Amornsupak,T. Insawang,P. Thuwajit,S. Pelden,B. Karaca,H. Atmaca,K. Asli,E. Bozkurt,B. Cakar,Z.G. Surmeli,P. Gursoy,B. Karabulut,S. Uzunoglu,C. Sezgin,T. Ahrends,P. Nowialis,H.L.F. Swa,W. Blackstock,L. Lim,J. Gunaratne,M. Stankic,S. Pavolvic,R. Benezra,U. Muslu,R. Uslu +118 more
TL;DR: It is suggested that AP-1 is critical in a switch in the ER transcriptional program and may be a new hallmark of endocrine resistance and circumvents resistance to endocrine therapy.
3
HORMAD1 drives spindle assembly checkpoint defects and sensitivity to multiple mitotic kinases
Callum Walker,Daniel Weekes,Gonzalo Torga,Jelmar Quist,Jennifer Trendell,L. Hitchens,A. Martin,K. Davidson,Gabriel Kollarovic,A. Grigoriadis,Jonathon Pines,Stephan Pettitt,C. Lord,A. Tutt +13 more
TL;DR: In this article , the authors identify and target effects associated with HORMAD1 expression in breast cancer cells, and highlight several therapeutic targets for a large subset of breast cancers that express HORMANAD1.
Abstract ES6-4: Parp inhibitors for brca1/2mutation associated breast cancer
TL;DR: The lecture will both explore the data and the implications for practice of the adoption of these guidelines and some of the ongoing questions to be addressed by ongoing clinical trial and translational research initiatives.